General
Preferred name
CISAPRIDE
Synonyms
Prepulsid ()
R 51619 ()
Pridesia ()
Kaudalit ()
(±)-Cisaprid ()
Kinestase ()
(¡À)-Cisaprid ()
Cisapride (monohydrate) ()
R 51619 (monohydrate) ()
(±)-Cisaprid (monohydrate) ()
(R,S)-CISAPRIDE MONOHYDRATE ()
Cisapride ()
Cisapride-d6 ()
P&D ID
PD009896
CAS
104860-66-4
81098-60-4
260779-88-2
Tags
available
drug
Drug indication
Gastroesophageal reflux disease
Gastrointestinal disease
Drug Status
approved
withdrawn
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist; upon activation of the receptor signaling pathway, cisapride promotes the release of acetylcholine neurotransmitters in the enteric nervous system. Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Cisapride increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder. Cisapride does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity.
DESCRIPTION Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity[1][2][3][4].
PRICE 51
DESCRIPTION 5-HT4 agonist; stimulates intestinal ACh release (Tocriscreen Plus)
DESCRIPTION 5-HT4 agonist; stimulates intestinal ACh release (Tocriscreen Total)
DESCRIPTION Cisapride (R 51619) is a serotonin type 4 (5-HT4) receptor agonists are potent prokinetic agents that act on serotonin receptors in the intestine and promote intestinal peristalsis, increase gastric emptying and decrease esophageal reflux. (TargetMol Bioactive Compound Library)
Compound Sets
15
Cayman Chemical Bioactives
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
465.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
9
Ring Count
3
Aromatic Ring Count
2
cLogP
3.36
TPSA
86.05
Fraction CSP3
0.43
Chiral centers
2.0
Largest ring
6.0
QED
0.44
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
5-HT
5-HT Receptor
HERG
Potassium Channel
HTR2A, HTR3A, HTR4, KCNH2
MOA
5-HT Receptor antagonist
Potassium Channel inhibitor
alpha-Adrenoceptor Antagonists
serotonin receptor agonist
Member status
virtual
Therapeutic Class
Gastrointestinal Agents
Pathway
GPCR/G protein
Membrane Transporter/Ion Channel
Neuronal Signaling
Neuroscience
Source data